Latest news : SynAct Pharma AB

09:53am	SynAct Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06:42am	Synact Pharma reports narrower operating loss	FW
05:03am	Calendar Thursday, August 20	FW
08-19	Synact Pharma signs term sheet with Hipolabor on resomelagon in Brazil	FW
08-06	SynAct Pharma Secures Appellate Board Backing in US Patent Application	MT
08-05	Buy rating lifted Nederman, OMXS30 index unchanged	FW
08-05	Synact Pharma gets positive US patent ruling for resomelagon (update)	FW
08-05	Synact Pharma gets favorable US patent ruling for resomelagon	FW
08-05	Synact Pharma receives favorable US patent decision on appeal regarding tablet formulation	FW
08-05	SynAct Pharma AB Receives Favorable US Patent Decision For Immediate-Release Resomelagon Tablet Formulation	CI
07-20	SynAct Pharma Draws SEK50 Million from New Financing Facility	MT
07-20	Synact Pharma secures access to financing of up to €9.0m	FW
07-20	Synact Pharma secures access to strategic financing facility of up to SEK 100m	FW

More news

Last Transcript: SynAct Pharma AB

SynAct Pharma AB - Special Call

06-15

More transcripts

Analysts' recommendations: SynAct Pharma AB

06-18	Edison Maintains Its Valuation for Synact Pharma After Trial Results	FW
03-04	Edison Raises Valuation of Synact Pharma - Commissioned Analysis	FW
02-09	Redeye Raises Target Price for Synact Pharma to 31 Kronor (26)	FW
31/10/25	Redeye Raises Target Price for Synact Pharma to 26 Kronor (25)	FW
28/10/25	Edison Initiates Coverage of Synact Pharma, Assigns Value of SEK 36.9 Per Share	FW

More recommendations

Press Releases: SynAct Pharma AB

06:31am	SynAct Pharma publishes Q2 2026 interim results	AQ
08-19	SynAct Pharma: Term Sheet Signed for Brazil	AQ
08-19	SynAct Pharma progresses first commercial agreement on resomelagon for treatment of dengue in Brazil – term sheet signed	AQ
08-05	SynAct Pharma receives favorable US patent decision for immediate-release resomelagon tablet formulation	AQ
07-20	SynAct comments on the SEK 100 million facility	AQ

More press releases

Managers and Directors: SynAct Pharma AB

Manager	Title	Age	Since
Jeppe Øvlesen CEO	Chief Executive Officer	64	31/12/2013
Ann Kristin Led DFI	Director of Finance/CFO	-	28/02/2026
Kirsten Harting CTO	Chief Tech/Sci/R&D Officer	-	14/02/2024

Director	Title	Age	Since
Jeppe Øvlesen BRD	Director/Board Member	64	19/03/2024
Anders Kronborg CHM	Chairman	62	19/03/2024
Sten Scheibye BRD	Director/Board Member	74	19/03/2024

More insiders

SynAct Pharma AB is a manufacturer of biological products. The Company is located in Lund, Sweden. It develops medicines for acute impairment in inflammatory diseases. The company's drug candidate AP1189 is intended for the treatment of arthritis including psoriasis arthritis.

Employees

Sector

Pharmaceuticals

Calendar

08-19 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
20/08/26	SEK 19.76	-7.88%	192,522
19/08/26	SEK 21.45	+7.25%	447,400
18/08/26	SEK 20.00	+1.11%	59,018
17/08/26	SEK 19.78	-0.80%	109,127
14/08/26	SEK 19.94	-1.04%	124,770

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Delayed Nasdaq Stockholm 09:50:15 20/08/2026 BST			5-day change	1st Jan Change
19.76 ^SEK	-7.88%		-1.94%	-12.57%

Market Cap	1.2B 127M 109M 102M 93.39M 176M 12.15B 179M 470M 6.09B 477M 467M 20.14B	P/E 2026 *	-14.4x	P/E 2027 *	-28.2x
Enterprise Value	1.18B 125M 107M 100M 92.04M 173M 11.97B 176M 464M 6B 470M 460M 19.85B	EV / Sales 2026 *	8.53x	EV / Sales 2027 *	58x
Free-Float	70.28%	Yield 2026 *	-	Yield 2027 *	-

1 day	-7.88%
1 week	-1.94%
Current month	+8.21%
1 month	+6.24%
3 months	+37.60%
6 months	-0.20%
Current year	-12.57%

1 week	19.02	22.2
1 month	17.08	22.2
Current year	7.05	24.4
1 year	7.05	25.3
3 years	4.98	124.6
5 years	4.98	146
10 years	4.8	146

Date	Insider	Type	Main position	Quantity	% Market Cap.
06/03/26	Thomas Boesen	Buy	Chief Operating Officer	2,750	0.0052%
31/12/25	Thomas Jonassen	Buy	Chief Technology Officer	3,529	0.0066%
22/12/25	Mads Bjerregaard	Buy	Executive/Senior Manager	1,500	0.0028%

SynAct Pharma AB Share Price

Stocks

SYNACT

SE0008241491

Pharmaceuticals

Valuation: SynAct Pharma AB

Chart: SynAct Pharma AB

Latest news : SynAct Pharma AB

Last Transcript: SynAct Pharma AB

Analysts' recommendations: SynAct Pharma AB

Press Releases: SynAct Pharma AB

Quotes and Performance

Course Extremes

Managers and Directors: SynAct Pharma AB

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SYNACT PHARMA AB	-7.88%	-1.94%	+10.51%	-80.28%	127M
ELI LILLY AND COMPANY	+4.46%	+4.92%	+82.07%	+134.31%	1,141B
JOHNSON & JOHNSON	+0.85%	+4.81%	+53.77%	+58.51%	659B
ABBVIE INC.	+2.72%	+6.92%	+28.99%	+77.15%	470B
ROCHE HOLDING AG	+0.42%	+1.88%	+40.66%	+45.14%	366B
NOVARTIS AG	+0.03%	+2.83%	+24.31%	+41.38%	302B
ASTRAZENECA PLC	-0.54%	+2.44%	+0.15%	+12.37%	254B
AMGEN INC.	+4.02%	+6.29%	+49.67%	+68.96%	239B
NOVO NORDISK A/S	-0.19%	+0.23%	-13.50%	-52.59%	207B
GILEAD SCIENCES, INC.	+2.90%	+8.63%	+25.11%	+94.52%	183B
Average	+0.30%	+4.81%	+30.18%	+39.95%	382.11B
Weighted average by Cap.	+1.06%	+4.31%	+46.76%	+74.10%

	2026 *	2027 *
Net sales	139M 14.68M 12.59M 11.76M 10.79M 20.29M 1.4B 20.62M 54.33M 704M 55.12M 53.92M 2.33B	21.15M 2.24M 1.92M 1.79M 1.64M 3.09M 214M 3.14M 8.28M 107M 8.4M 8.22M 355M
Net income	52.18M 5.52M 4.74M 4.42M 4.06M 7.63M 528M 7.75M 20.43M 265M 20.73M 20.28M 875M	-26.04M -2.76M -2.36M -2.21M -2.03M -3.81M -263M -3.87M -10.2M -132M -10.35M -10.12M -437M
Net Debt	-17.48M -1.85M -1.59M -1.48M -1.36M -2.56M -177M -2.6M -6.84M -88.66M -6.94M -6.79M -293M	24.86M 2.63M 2.26M 2.11M 1.93M 3.63M 251M 3.69M 9.73M 126M 9.88M 9.66M 417M